Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent

Alcohol Dependence Clinical Trial

— SPAD  

Official title:

A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01842503
• Other study ID #: 73CT-2-03
• Secondary ID: 2012-005515-13
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2014
• Est. completion date: November 2018

Study information

• Verified date: April 2019
• Source: Laboratorio Farmaceutico Ct S.r.l.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Examination of the effect of GET 73 on alcohol pharmacokinetics and pharmacodynamics (intoxication and sedation)and safety profile in alcohol-dependent individuals.To evaluate whether GET 73, as compared to placebo, results in diminished cue-reactivity responses to alcohol cues in terms of urge to drink during the cue reactivity session and results in lower quantity of alcohol consumed during an alcohol self-administration session.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: November 2018
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• male or female subjects, between 21 and 65 years old (inclusive);

• participants must meet criteria for current Diagnostic and Statistical Manual (DSM-IV)diagnosis of alcohol dependence,supported by the structured clinical interview for DSM-IV Axis I Disorders Patient Edition;

• participants must meet criteria for heavy drinking, defined as averaging

• 4 drinks/day for women and =5 drinks/day for men during a 30-day period within the 90 days prior to screening evaluation;

• participants must be in good health as confirmed by medical history, physical examination, ECG, lab tests;

• females must be postmenopausal for at least one year or surgically sterile. Otherwise, females will be excluded (even if they are using any kind of birth control). Proof (medical records, certification from an medical doctor) of surgical sterility will be required. Certification of postmenopausal for at least 1 year and postmenopausal levels of FSH will also be required to be into the study;

• participants must be willing to take oral medication and adhere to the study procedures;

• participants must give their consent to enter the study by signing the informed consent form.

Exclusion Criteria:

• individuals seeking treatment for alcohol dependence;

• positive urine drug screen at baseline for positive drug screen for the following:

opioids, benzodiazepines, cocaine, methamphetamine or any other stimulants. A urine drug screen may be repeated once and must test negative before randomization;

• individuals diagnosed with a current substance dependence, other than alcohol or nicotine;

• meet DSM-IV Axis I criteria for a lifetime diagnosis of schizophrenia, bipolar disorder, or other psychoses;

• Subjects taking any psychoactive medication that in the opinion of the subjects primary care physician, cannot be discontinued at least 14 days prior to being randomized;

• an active illness within the past 6 months of Visit 1 that meet the DSM-IV criteria for a diagnosis of Major Depressive Disorder or Anxiety Disorder;

• subjects with a history of suicide attempts and/or at risk for suicide will be excluded, based on the Structured Clinical Interview Disorders assessment and on the Investigators' evaluation;

• clinically significant medical abnormalities (i.e., unstable hypertension, clinically significant abnormal ECG, bilirubin > 150% of the upper normal limit, alanine aminotransferase or aspartate aminotransferase elevations >300% the upper normal limit, estimated creatinine clearance = 60 dl/min);

• current use of any medications prescribed to reduce alcohol use e.g. naltrexone, acamprosate, disulfiram or topiramate;

• concomitant use of cytochromeP450 2C19 substrates; assumption of cytochromeP450 2C19 and cytochromeP450 3A4 inhibitors or inducers in the 14 days before dosing;

• individuals with a reasonable expectation of being institutionalized during the course of the trial;

• participants who have significant alcohol withdrawal symptoms, defined as a Clinical Institute Withdrawal Assessment >10;

• history of seizures (e.g. epilepsy), including alcohol-related seizures;

• history of delirium tremens;

• subjects who have participated in any behavioral and/or pharmacological study within the past 30 days;

• history of delirium tremens.

Related Conditions & MeSH terms

• Alcohol Dependence
• Alcoholism

Intervention

Drug:
• GET 73
300 mg tid on 3 days cycle
• inactive ingredients capsule
3 capsules tid on 3 days cycle

Locations

Country	Name	City	State
United States	Roger Williams Medical Center	Providence	Rhode Island

Sponsors (4)

Lead Sponsor	Collaborator
Laboratorio Farmaceutico Ct S.r.l.	Latis S.r.l., Quotient Bioresearch, Voisin Consulting, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	changes in area under the plasma concentration of alcohol versus time curve (AUC), after administration of GET 73 or placebo	On Day 2 and Day 12 subjects have an indwelling catheter placed in a forearm vein for blood draws. After the 5th dose of GET 73 or placebo is administered on Day 2 and Day 12, participants receive a dose of alcohol 30 minutes later, which is calculated to produce a peak of 0.08 g/L, based on body water content.; AUC will be evaluated as mean value of overall subjects evaluated	blood samples are drawn on day 2 and day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
Primary	Changes in pleasurable and negative effects of alcohol intoxication and sedation, measured by the Biphasic Alcohol Effects Scales (BAES),during the Alcohol Self-Administration (ASA) session, when taking GET 73 compared to placebo.		The BAES will be administered, at Day 2 and Day 12, eight times after the priming drink is presented during the ASA.
Primary	Changes in reaction time, measured by Conners's Continuous Performance Task (CPT),when taking GET 73 compared to placebo		CPT will be assessed at Day 2 and Day 12
Primary	Changes in cognitive performance, measured by Digit Symbol Substitution Test (DSST), when taking GET 73 compared to placebo		DSST will be assessed at Day 2 and Day 12
Primary	Frequency of adverse events (AEs) occured after placebo or GET 73 administration	All AEs occurring during the study will be recorded. Subjects are discharged from the hospital at Day 13, after the two inpatient treatment phases (Day 1-Day 3 and Day 11-Day 13). A follow-up visit, approximately from 7 to 14 days after the second CR/ASA experiment, will be performed. The AEs will be grouped by Medical Dictionary for Regulatory Affairs preferred terms into frequency tables according to system organ class (SOC).; Frequencies of AEs occurred after placebo or GET 73 administration will be compared using chi-square or Fischer's exact test.	up to 20-27 days
Primary	Changes in cue reactivity (CR) responses to alcohol cues, in terms of urge to drink, as measured by the Alcohol Urge Questionnaire (AUQ), when taking GET 73 compared to placebo.	To evaluate whether GET 73, as compared to placebo, results in reductions in craving (as measured by the AUQ), the AUQ will be administered eight times after the priming drink is presented during the ASA.	At Day 3 and Day 13 during the two treatment phases
Primary	Changes in CR responses to alcohol cues, in terms of psychophysiological responses,heart rate,mean arterial pressure and salivation changes during the CR session.	There are three experimental time periods of 3-minutes each during each CR session. Cotton swabs will be weighed at the end of each 3-minute block and the mean values for weight of salivation will be calculated. An average heart rate and an average mean arterial pressure will be calculated for each of these three time periods.	At Day 3 and Day 13 during the two treatment phases
Primary	Changes in attention to the sight and smell of cues, as measured by Alcohol Attention Scale (AAS), during the CR.		This endpoint will be measured twice in each CR session (Day 3 and Day 13) through the AAS.
Primary	Effects of GET 73 on the amount of alcohol consumed during the ASA. The maximum quantity of alcohol will be taken, to have a measure directly comparable to AUQ results		At Day 3 and Day 13 during the two treatment phases
Primary	Changes in peak plasma concentration (Cmax) of alcohol after administration of GET 73 or placebo	Cmax will be calculated at the peak level as mean value of overall subjects evaluated	blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
Primary	Changes in time to peak plasma level (Tmax) of alcohol after administration of GET 73 or placebo	Tmax will be evaluated as the time after administration corresponding to the time of peak plasma level and as mean value of overall subjects evaluated	blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
Primary	Changes in half-life of alcohol after administration of GET 73 or placebo	Half-life will be calculated as mean value of overall subjects evaluated	blood samples are drawn on Day 2 and Day 12 at baseline and then, following the start of alcohol consumption, for the next 8 hours or until the blood alcohol level is zero on 2 successive determinations
Primary	Characteristics of adverse events (AEs) occured after placebo or GET 73 administration	All AEs occurring during the study will be recorded. Subjects are discharged from the hospital at Day 13, after the two inpatient treatment phases (Day 1-Day 3 and Day 11-Day 13). A follow-up visit, approximately from 7 to 14 days after the second CR/ASA experiment, will be performed. The AEs will be grouped by Medical Dictionary for Regulatory Affairs preferred terms according to system organ class (SOC). When an AE occurs more than once for a subject, the maximal severity and strongest relationship to the medication will be counted.; Characteristics of AEs occurred after placebo or GET 73 administration will be compared using chi-square or Fischer's exact test.	up to 20-27 days